Education
About Us
Working with TipRanks
Follow Us
Compugen (CGEN)
:CGEN
Normal Saline, Com701
Ovarian Cancer, Ovarian Cancer Recurrent
Phase I/II
Recruiting
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
Mar 12, 2025
―
Dose Escalation: Com902 Monotherapy., Evaluation Of Safety/Tolerability: Com902 In Combination With Com701 (Both At The Rdfe), Cohort Expansion: Com902 (Rdfe) Monotherapy., Cohort Expansion: Com902 In Combination With Com701 (Both At The Rdfe)., Cohort Expansion: Triplet Combination Of Com902 + Com701 + Pembrolizumab.
Multiple Myeloma, Ovarian Cancer, Lung Cancer, Advanced Cancer, Hnscc, Colon Cancer, Plasma Cell Neoplasm, Microsatellite Stable Colorectal Carcinoma, Mss-Crc
Phase I
Active Not Recruiting
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Apr 15, 2020
―
Com701, Com701 With Opdivo (Nivolumab).
Ovarian Cancer, Breast Cancer, Triple Negative Breast Cancer, Lung Cancer, Advanced Cancer, Neoplasm Malignant, Endometrial Cancer, Colo-Rectal Cancer, Ovarian Neoplasm, Lung Neoplasm
Phase I
Completed
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
Sep 10, 2018
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Compugen (CGEN) have in its pipeline
CGEN is currently developing the following drugs: Normal Saline, Com701, Dose Escalation: Com902 Monotherapy., Evaluation Of Safety/Tolerability: Com902 In Combination With Com701 (Both At The Rdfe), Cohort Expansion: Com902 (Rdfe) Monotherapy., Cohort Expansion: Com902 In Combination With Com701 (Both At The Rdfe)., Cohort Expansion: Triplet Combination Of Com902 + Com701 + Pembrolizumab., Com701, Com701 With Opdivo (Nivolumab).. These drug candidates are in various stages of clinical development as the company works toward FDA approval.